AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) (NCT07611110)
A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
🩺 Plain-English Summary (8th-Grade Level)
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Who can join: Review the eligibility criteria below.
Location: Research Site — Dothan, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (132 Sites)
Showing the first 25 of 132 sites.
- Research Site — Dothan, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Duarte, California
- Research Site — Irvine, California
- Research Site — Newport Beach, California
- Research Site — San Francisco, California
- Research Site — Aurora, Colorado
- Research Site — Miami, Florida
- Research Site — O'Fallon, Illinois
- Research Site — Metairie, Louisiana
- Research Site — Detroit, Michigan
- Research Site — Grand Rapids, Michigan
- Research Site — St Louis, Missouri
- Research Site — Omaha, Nebraska
- Research Site — Albuquerque, New Mexico
- Research Site — New Hyde Park, New York
- Research Site — New York, New York
- Research Site — Cleveland, Ohio
- Research Site — Dayton, Ohio
- Research Site — Portland, Oregon
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Myrtle Beach, South Carolina
- Research Site — Nashville, Tennessee
- Research Site — Houston, Texas
- Research Site — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration-resistant Prostate Cancer
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
- A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
- FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California
Explore by condition: All Metastatic Castration-resistant Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.